Guide
Japan Functional Food Readiness: FFC, FOSHU/Tokuho and the CAA Three-Track Framework Post Red Yeast Rice
Japan has a three-track functional food framework administered by the Consumer Affairs Agency (CAA) under the Food Labeling Act: FOSHU (Tokuho — pre-market government efficacy review), Foods with Nutrient Function Claims (a CAA-published list of permitted nutrient claims, no notification needed), and Foods with Function Claims (FFC — self-substantiated function claims with pre-marketing notification, the fastest-growing track since its 2015 introduction). The 2024 red yeast rice (紅麹) incident did not change the pre-market mechanics but materially raised post-market surveillance, GMP and adverse-event expectations on FFC supplement-format products. This guide maps the three tracks for international brands entering the Japanese functional channel.
Start free trial Free trial, no credit card, onboard in days, not months.
The three tracks — pick the right channel for the claim
Track 1: FOSHU / Tokuho (特定保健用食品) — Foods for Specified Health Use. Pre-market government scientific review by the Food Safety Commission and CAA, full clinical evidence on the product itself (not a surrogate). 24-36 months and significant cost. The most rigorous track, used for established functional claims and category-defining products. Track 2: Foods with Nutrient Function Claims (栄養機能食品) — claims on 20 vitamins and 5 minerals from a CAA-published list, no notification needed but only the published claims at the published dose ranges. Track 3: FFC (機能性表示食品) — Foods with Function Claims. Self-substantiation by systematic review or own clinical trial, pre-marketing notification with the CAA at least 60 days before sale, no efficacy review but the substantiation is publicly visible on the CAA database. Most international supplements entering Japan use Track 3 because Track 1 is slow and expensive and Track 2 caps the claim universe.
FFC notification — the dossier behind the database entry
An FFC notification is a public dossier on the CAA database, not a confidential filing. It must include: company information, product information (formulation, dose, target population), the functional claim wording, the safety basis (toxicology, intake history, adverse-event review), the efficacy basis (a systematic review meeting CAA SR guidance, or an in-house clinical trial), the quality control basis (manufacturing GMP, in-process and finished-product testing), and the post-market vigilance plan. The notification is reviewed administratively for completeness — not for scientific merit. The CAA can challenge the substantiation post-market, and the dossier visibility means competitors, academic critics and journalists can audit it.
Post-2024 red yeast rice — the surveillance and GMP step-up
The March 2024 Kobayashi Pharmaceutical red yeast rice (紅麹) incident, in which contaminated benikoji supplements were linked to kidney injury and deaths, triggered a substantial CAA tightening on FFC. Pre-market mechanics did not change — FFC is still a notification, not a review. What changed: mandatory adverse-event reporting timelines tightened, GMP expectations on FFC supplement-format products materially raised (toward PE 009 / pharmaceutical-grade rather than food-grade), supply-chain due diligence on fermentation-derived and botanical ingredients explicitly required, and CAA database updates on safety signals expedited. International brands taking the FFC route into Japan after 2024 are walking into a more scrutinised regime than 2015-2023 entrants.
Labelling — Japanese language, the disclaimers and the FFC distinguishing marks
All functional food labels are in Japanese. FOSHU products carry the FOSHU mark (a smiling figure raising arms). FFC products carry the words 機能性表示食品 prominently on the front of pack alongside the function claim and several mandatory disclaimers: 'This food is not intended to diagnose, treat or prevent disease' (本品は、疾病の診断、治療、予防を目的としたものではありません), the daily intake, intake instructions, the precautions, the manufacturer or seller, and the FFC notification ID. Foods with Nutrient Function Claims have their own format with the nutrient name and the prescribed claim wording. Misuse of the FFC indication (claiming FFC without notification, or using the FFC wording on a non-FFC product) is a Food Labeling Act violation.
A 180-day Japan FFC entry path
Days 1–25: track decision (FFC unless the claim and product clearly suit Nutrient Function or FOSHU), in-country agent or subsidiary setup, formulation review against the FFC ingredient expectations. Days 26-70: substantiation — systematic review under CAA guidance or in-house clinical trial. Days 71-100: safety basis assembly (intake history, toxicology, adverse-event literature), GMP attestation to the post-2024 supplement-grade expectation, Japanese label build with the FFC mark and disclaimers. Days 101-120: CAA pre-marketing notification submission (60 days before sale, minimum). Days 121-150: customs clearance, distributor onboarding, post-market vigilance plan activation. Days 151-180: launch, first adverse-event reporting cycle, retailer due-diligence responses.
Standards covered in this guide
Each standard, retailer code or assurance scheme referenced above has its own deep-dive page with scope, audit detail and common pitfalls.
FFC
Japan's CAA-notified food-with-function-claim regime — self-substantiated function claims without pre-market approval, distinct from FOSHU and Foods with Nutrient Function Claims.
Tokuho
Japan's pre-market reviewed functional food category — full government scientific evaluation of efficacy and safety, the most rigorous of the three CAA functional food tracks.
Where this lives in V5 Ultimate
The clauses above aren't theoretical — every one maps to a shipped module and an industry profile. Jump to the parts of the product that turn this guide into evidence on a Monday morning.
Modules that do the work
FFC notification dossier on one SKU spine
Substantiation, safety basis, GMP, vigilance plan assembled.
Post-2024 supplement-grade GMP evidence
PE 009-aligned GMP attestation, supplier due diligence per SKU.
CAA adverse-event reporting timelines
AE log tied to Japan reporting clock, not a separate system.
Industries this hits hardest
Frequently asked
Is FFC pre-market approval by the CAA?
No. FFC is a pre-marketing notification — the company self-substantiates the function claim by published systematic review or its own clinical trial, files the dossier with the CAA at least 60 days before sale, and the dossier is published on the CAA database. The CAA does not review efficacy pre-market; it can challenge the substantiation post-market. FOSHU/Tokuho is the pre-market review track.
Do I need a Japanese in-country agent for FFC?
Yes, in practice. The FFC notifier must be the company placing the product on the Japanese market. International brands typically appoint a Japanese subsidiary or a third-party in-country agent to be the notifier of record, to hold the adverse-event reporting responsibility, and to be the CAA point of contact for post-market queries.
How did the 2024 red yeast rice incident change FFC?
Pre-market mechanics did not change. Post-market expectations rose substantially: adverse-event reporting timelines tightened, GMP expectations on FFC supplement-format products raised toward pharmaceutical-grade, supply-chain due diligence on fermentation-derived and botanical ingredients explicitly required, and CAA safety-signal database updates expedited. New FFC entrants after 2024 face a more scrutinised regime.
Which Japan track should an international brand pick?
FFC for almost all functional supplement entries — fastest, no efficacy review, claim flexibility constrained only by what the substantiation supports. Nutrient Function Claims when the claim is on one of the 20 vitamins or 5 minerals at the prescribed dose, with no notification overhead. FOSHU/Tokuho only when the brand wants the government efficacy mark for a category-defining product and can absorb 24-36 months and clinical study cost.
See it on your shop floor.
Free trial, no credit card, onboard in days, not months.
Related reading
- 10 CFR 35 medical use readiness — NRC licensing for radiopharmaceuticals
- 21 CFR 111 Readiness: Dietary Supplement cGMP Subparts E & F
- 21 CFR 211 Drug cGMP Readiness Guide
- 21 CFR 212 PET drug cGMP readiness — FDA inspection playbook
- 21 CFR 589 BSE / Ruminant Feed Ban Readiness Guide
- 21 CFR 820 to ISO 13485 Mapping Guide (Including QMSR Harmonisation)
Spot something off? .